Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726280 | 0.87 | DHODH (0.46) | KDM4EALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL6726432 | 0.86 | DHODH (0.49) | KDM4EALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL6724797 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HRH3SMN1; SMN2 | |
| SCHEMBL6724740 | 0.83 | PRKAB2 (0.52) | KDM4EALDH1A1HRH3 | |
| SCHEMBL6724501 | 0.82 | ALDH1A1 (0.46) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6734639 | 0.81 | HRH3 (0.41) | HRH3 | |
| SCHEMBL6726264 | 0.80 | PRKAB2 (0.53) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6724521 | 0.78 | PRKAB2 (0.46) | KDM4EALDH1A1 | |
| SCHEMBL6669224 | 0.77 | PRKAB2 (0.34) | KDM4EALDH1A1HRH3 | |
| SCHEMBL6733358 | 0.76 | PRKAB2 (0.37) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | disclosed |